|
|
Volumn 32, Issue 1, 1998, Pages 1-5
|
|
Cancer drug development: Problems and opportunities
|
|
Author keywords
Cancer; Oncologic drug development; Pharmaceutical industry
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ACTIVITY;
CANCER CHEMOTHERAPY;
CANCER MORTALITY;
CANCER PATIENT;
CANCER SURVIVAL;
CLINICAL TRIAL;
HUMAN;
LUNG CANCER;
MORTALITY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REVIEW;
RISK ASSESSMENT;
|
|
EID: 0031942291
PISSN: 00928615
EISSN: None
Source Type: Journal
DOI: 10.1177/009286159803200101 Document Type: Review |
|
Times cited : (1)
|
|
References (0)
|
